Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.61 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | WDR5 | P61964 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.61 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.61 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.61 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.61 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexlansoprazole SCHEMBL29950208 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29353881 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29353345 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29598842 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29358567 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29750802 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1559598 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL44975 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28982 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| US-12622875-B2 | Dosage form comprising an alkaline agent and an enteric coating layer | EVONIK OPERATIONS GMBH (DE) | 2026-05-12 | — | — | US | claimed |
| EP-4735895-A1 | HELICOBACTER CAGA PEPTIDES AND THEIR USE IN DIAGNOSIS | Biotome Pty Ltd (AU) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731180-A1 | A POWDER COMPOSITION FOR ORAL SUSPENSION OF PROTON PUMP INHIBITORS AND THE METHOD OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-04-29 | — | — | EP | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260097026-A1 | INHIBITION OF AORTIC VALVE CALCIFICATION | ZABIRNYK ARSENII (NO) | 2026-04-09 | — | — | US | claimed |
| US-20260091116-A1 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | AZURITY PHARMACEUTICALS, INC. | 2026-04-02 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| WO-1992008716-A1 | SEPARATION OF ENANTIOMERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-05-29 | — | — | WO | claimed |
| EP-0446961-A2 | Stabilized pharmaceutical composition and its production | Takeda Chemical Industries, Ltd. (JP) | 1991-09-18 | — | — | EP | claimed |
| US-5026560-A | Coated with binder and spraying powder containing drug; low substitutes hydroxypropyl cellulose; hardness; dosage forms of e.g. lansoprazole | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-25 | — | — | US | claimed |
| US-5013743-A | Use of substituted pyridylmethylsulfinyl- and pyridylmethylthiobenzimidazoles such as lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl)methylthiobenzimidazole | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-07 | — | — | US | claimed |
| EP-0423748-A1 | Stabilized pharmaceutical composition and its production | Takeda Chemical Industries, Ltd. (JP) | 1991-04-24 | — | — | EP | claimed |
| EP-0382489-A2 | Use of benzimidazole derivatives as antibacterial agents | Takeda Chemical Industries, Ltd. (JP) | 1990-08-16 | — | — | EP | claimed |
| EP-0174726-B1 | PYRIDINE DERIVATIVES AND THEIR PRODUCTION | Takeda Chemical Industries, Ltd. (JP) | 1989-04-26 | — | — | EP | claimed |
| EP-0237200-A2 | Use of basic inorganic salts of magnesium or calcium for the stabilisation of benzimidazole derivatives | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | claimed |
| US-4628098-A | Including Prevacid (TM) lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)-5-methyl-pyrid-2 -yl)methylsulfinylbenzimidazole; proton pump inhibitors, antiulcer, antisecretory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-12-09 | — | — | US | claimed |
| EP-0174726-A1 | Pyridine derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1986-03-19 | — | — | EP | claimed |